Located in Schlieren, Switzerland, the Roche Innovation Center Zurich serves as a hub of excellence for oncology research, particularly focusing on Cancer Immunotherapy. Through a collaborative approach that integrates Pharmaceutical Science and Data & Analytics with Discovery and Early Development Oncology, the center aims to develop groundbreaking medicines. Originally founded as Glycart Biotechnology AG in 2000 as an ETH Zurich spin-off, it was acquired by Roche in 2005 and now plays a vital role in Roche Pharma Research and Early Development (pRED).
The cutting-edge research facility in Schlieren is one of five Roche Pharma Research and Early Development Innovation Centers globally. With a diverse team of multinational research scientists, the center fosters a vibrant biotech culture. Research teams at the Roche Innovation Center Zurich are dedicated to pioneering advancements in cancer immunotherapy and targeted cancer cell therapy. These teams are part of the oncology DTA Discovery, Early Development Oncology, as well as global functions like Pharmaceutical Sciences, Data & Analytics, and Operations. Additionally, the center collaborates with a satellite team from the Institute of Human Biology, focusing on research in organoids, human model systems, and translational bioengineering.
The primary focus at Roche Innovation Center Zurich is on product development, ranging from initial scientific concepts to validation and subsequent studies. The compounds under investigation and development here are pivotal in advancing Roche’s commitment to providing enhanced cancer treatments. With over 90,000 employees working together across more than 100 countries, Roche is significantly contributing to the field of oncology research and drug development.
Key Takeaways:
– Roche Innovation Center Zurich is a key player in Roche Pharma Research and Early Development, focusing on Cancer Immunotherapy.
– The center, originally Glycart Biotechnology AG, was acquired by Roche in 2005 and is renowned for its cutting-edge research.
– Research teams at the center collaborate on developing innovative cancer therapies, with a special emphasis on cancer immunotherapy and targeted cell therapy.
– Roche’s commitment to improving cancer treatments is evident through the work conducted at the Innovation Center Zurich.
Tags: biotech, immunotherapy
Read more on roche.com